Epiminder Secures US$31,265 Medicare Payment Rate for Minder System in CY2027

Mukul

06 November 2026 11:23 AM AEDT

Epiminder Secures US$31,265 Medicare Payment Rate for Minder System in CY2027

Image Source: Krish Capital Pty Ltd

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Epiminder Limited (ASX:EPI) has disclosed that the Centers for Medicare & Medicaid Services (CMS) has finalised the CY2027 Hospital Outpatient Prospective Payment System rule, assigning the Minder System implant procedure a national Medicare payment rate of US$31,265, compared to US$27,700 in 2026, with the payment taking effect on January 1, 2027.

Key Points

CMS has assigned the Minder System implant procedure to Ambulatory Payment Classification (APC) 5117 with a national Medicare payment rate of US$31,265 for CY2027.
The CY2027 rate of US$31,265 compares to the CY2026 rate of US$27,700, representing a 13% increase as stated in the filing.
The Medicare payment rate takes effect January 1, 2027, covering hospital costs for the procedure including the implanted device in the outpatient setting.
The company expects to reach 125 participants in its DETECT study by December 2026, following enrolment of the 100th participant announced in mid-October 2026.

CY2027 Medicare Payment Rate and APC Assignment

CMS has finalised the CY2027 Hospital Outpatient Prospective Payment System (OPPS) rule, assigning the Minder System implant procedure to APC 5117. The national Medicare payment rate of US$31,265 covers the hospital's costs for the procedure, including the implanted device. The national rate is adjusted for local wage levels at each hospital. Because the Minder System is implanted through a minimally invasive subscalp procedure, the hospital outpatient department is described in the filing as a natural setting of care, making this payment rate central to how US hospitals will evaluate and adopt the technology.

Minder System Background and FDA Authorisation

The Minder System is a minimally invasive implantable continuous EEG Monitoring (iCEM) device that provides clinicians and patients with long-term, objective data on brain electrical activity. The system continuously records bilateral subscalp EEG and transmits data via an external wearable and smartphone application to a secure cloud platform. The Minder System was authorised by the US Food and Drug Administration via the de novo pathway and is currently being used in the DETECT post-market study as a marketed device. The filing also references an expanded paediatric clearance issued by the FDA the prior week.

DETECT Study Enrolment and Company Expectations

Epiminder disclosed that the 100th participant enrolled in the DETECT study was announced in mid-October 2026. The company expects to reach 125 participants in DETECT by December 2026, according to the filing. The Medicare 2027 payment determination is described in the filing alongside the FDA paediatric clearance expansion and DETECT enrolment progress. The filing also references the UMPIRE first-in-human multicentre trial, published in Epilepsia in 2025, which the filing states demonstrated the Minder System's safety and high-quality signal acquisition across extended monitoring periods.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.